TY - JOUR
T1 - Genetic requirements for the survival of tubercle bacilli in primates
AU - Dutta, Noton K.
AU - Mehra, Smriti
AU - Didier, Peter J.
AU - Roy, Chad J.
AU - Doyle, Lara A.
AU - Alvarez, Xavier
AU - Ratterree, Marion
AU - Be, Nicholas A.
AU - Lamichhane, Gyanu
AU - Jain, Sanjay K.
AU - Lacey, Michelle R.
AU - Lackner, Andrew A.
AU - Kaushal, Deepak
N1 - Funding Information:
Received 8 October 2009; accepted 18 December 2009; electronically published 15 April 2010. Potential conflicts of interest: none reported. Financial support: Tulane Research Enhancement Fund (to D.K.), Louisiana Vaccine Center (to D.K.), Tulane Center for Infectious Diseases (to S.M.), and the National Institutes of Health (grants R21RR026006 [to D.K.], P20RR020159, and P51RR164). Presented in part: Keystone meeting on Tuberculosis: Biology, Pathology, and Therapy, Keystone, Colorado, 25–30 January 2009 (poster abstract #189). Reprints or correspondence: Dr Deepak Kaushal, Div of Bacteriology and Parasitology, Tulane National Primate Research Center, 18703 Three Rivers Rd, Covington, LA, 70433 ([email protected]).
PY - 2010/6/1
Y1 - 2010/6/1
N2 - Background. Tuberculosis (TB) leads to the death of 1.7 million people annually. The failure of the bacille Calmette-Guérin vaccine, synergy between AIDS and TB, and the emergence of drug resistance have worsened this situation. It is imperative to delineate the mechanisms employed by Mycobacterium tuberculosis to successfully infect and persist in mammalian lungs. Methods. Nonhuman primates (NHPs) are arguably the best animal system to model critical aspects of human TB. We studied genes essential for growth and survival of M. tuberculosis in the lungs of NHPs experimentally exposed to aerosols of an M. tuberculosis transposon mutant library. Results. Mutants in 108 M. tuberculosis genes (33.13% of all genes tested) were attenuated for in vivo growth. Comparable studies have reported the attenuation of only ∼6% of mutants in mice. The M. tuberculosis mutants attenuated for in vivo survival in primates were involved in the transport of various biomolecules, including lipid virulence factors; biosynthesis of cell-wall arabinan and peptidoglycan; DNA repair; sterol metabolism; and mammalian cell entry. Conclusions. Our study highlights the various virulence mechanisms employed by M. tuberculosis to overcome the hostile environment encountered during infection of primates. Prophylactic approaches aimed against bacterial factors that respond to such in vivo stressors have the potential to prevent infection at an early stage, thus likely reducing the extent of transmission of M. tuberculosis.
AB - Background. Tuberculosis (TB) leads to the death of 1.7 million people annually. The failure of the bacille Calmette-Guérin vaccine, synergy between AIDS and TB, and the emergence of drug resistance have worsened this situation. It is imperative to delineate the mechanisms employed by Mycobacterium tuberculosis to successfully infect and persist in mammalian lungs. Methods. Nonhuman primates (NHPs) are arguably the best animal system to model critical aspects of human TB. We studied genes essential for growth and survival of M. tuberculosis in the lungs of NHPs experimentally exposed to aerosols of an M. tuberculosis transposon mutant library. Results. Mutants in 108 M. tuberculosis genes (33.13% of all genes tested) were attenuated for in vivo growth. Comparable studies have reported the attenuation of only ∼6% of mutants in mice. The M. tuberculosis mutants attenuated for in vivo survival in primates were involved in the transport of various biomolecules, including lipid virulence factors; biosynthesis of cell-wall arabinan and peptidoglycan; DNA repair; sterol metabolism; and mammalian cell entry. Conclusions. Our study highlights the various virulence mechanisms employed by M. tuberculosis to overcome the hostile environment encountered during infection of primates. Prophylactic approaches aimed against bacterial factors that respond to such in vivo stressors have the potential to prevent infection at an early stage, thus likely reducing the extent of transmission of M. tuberculosis.
UR - http://www.scopus.com/inward/record.url?scp=77951883143&partnerID=8YFLogxK
U2 - 10.1086/652497
DO - 10.1086/652497
M3 - Article
C2 - 20394526
AN - SCOPUS:77951883143
SN - 0022-1899
VL - 201
SP - 1743
EP - 1752
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 11
ER -